ZNTL

Bunker Kevin D.

Known title: Chief Operating OfficerCIK: 0001807484

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 5, 2026

Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.

this person other insiders at ZNTL

Transaction History

ZNTL▼ Sell$0
ZNTL▼ Sell$99K
ZNTL▼ Sell$20K
ZNTL▼ Sell$2.4M
ZNTL▼ Sell$130K
ZNTL▼ Sell$78K
ZNTL▲ Buy$0
ZNTL▼ Sell$0
ZNTL▲ Buy$0
ZNTL▼ Sell$150K
ZNTL▼ Sell$150K
ZNTL▼ Sell$99K
ZNTL▼ Sell$51K
ZNTL▼ Sell$752K
ZNTL▼ Sell$140K
ZNTL▼ Sell$10K
ZNTL▼ Sell$3K
ZNTL▼ Sell$220K
ZNTL▼ Sell$271K
ZNTL▼ Sell$185K
ZNTL▼ Sell$203K
ZNTL▼ Sell$82K
ZNTL▼ Sell$122K
ZNTL▼ Sell$38K
ZNTL▼ Sell$310K
ZNTL▼ Sell$20K
ZNTL▼ Sell$81K
ZNTL▼ Sell$10K
ZNTL▼ Sell$144K
ZNTL▼ Sell$123K
ZNTL▼ Sell$164K
ZNTL▼ Sell$180K
ZNTL▼ Sell$68K
ZNTL▲ Buy$0
ZNTL▼ Sell$163K
ZNTL▼ Sell$394K
ZNTL▼ Sell$44K
ZNTL▼ Sell$212K
ZNTL▼ Sell$127K
ZNTL▼ Sell$155K
ZNTL▼ Sell$191K
ZNTL▼ Sell$0
ZNTL▼ Sell$167K
ZNTL▼ Sell$148K
ZNTL▼ Sell$310K
ZNTL▼ Sell$167K
ZNTL▼ Sell$31K
ZNTL▼ Sell$288K
ZNTL▼ Sell$30K
ZNTL▼ Sell$369K
ZNTL▼ Sell$760K
ZNTL▼ Sell$781K
ZNTL▼ Sell$0
ZNTL▼ Sell$0
ZNTL▼ Sell$92K
ZNTL▼ Sell$205K
ZNTL▼ Sell$246K
ZNTL▼ Sell$14K
ZNTL▼ Sell$0
ZNTL▼ Sell$0
ZNTL▼ Sell$256K
ZNTL▼ Sell$27K
ZNTL▼ Sell$284K

We use analytics to understand how market-wall is used. No personal data is sold.